Partnering is a cornerstone of our company’s growth and success.Through these collaborations, we deepen our capabilities with new tools, new resources, and new expertise.
Exclusive in vivo gene editing research and development collaboration and license agreement with Novartis to develop a single ARCUS nuclease designed as a potential single-administration treatment for hemoglobinopathies including sickle cell disease and beta thalassemia.
Research collaboration and exclusive license agreement with Prevail, a wholly owned subsidiary of Lilly, to use ARCUS genome editing technology for the research and development of potential in vivo therapies for genetic disorders, including Duchenne muscular dystrophy, and other CNS and liver-directed conditions.
License and collaboration agreement with iECURE to advance Precision’s PBGENE-PCSK9 candidate into Phase 1 studies and gain access to PCSK9-directed ARCUS nuclease to develop additional gene editing therapies.
Research, collaboration, and license agreement with the University of Pennsylvania to collaborate on the preclinical development for gene editing products involving the delivery of an ARCUS nuclease.
Option agreement to evaluate Acuitas Therapeutic Inc.’s lipid nanoparticle (LNP) technology for delivery of ARCUS with rights to license, develop, and commercialize LNP-delivered ARCUS products.
Global rights to azer-cel, allogeneic CAR T candidate for cancer. Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future.